Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.
Identifieur interne : 000E40 ( PubMed/Corpus ); précédent : 000E39; suivant : 000E41Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.
Auteurs : Amit C. Achhra ; Amanda Mocroft ; Michael Ross ; Lene Ryom-Nielson ; Anchalee Avihingsanon ; Elzbieta Bakowska ; Waldo Belloso ; Amanda Clarke ; Hansjakob Furrer ; Gregory M. Lucas ; Matti Ristola ; Mohammed Rassool ; Jonathan Ross ; Charurut Somboonwit ; Shweta Sharma ; Christina WyattSource :
- International journal of antimicrobial agents [ 1872-7913 ] ; 2017.
Abstract
The impact of early ART initiation (versus deferring) on kidney function has not been studied. START was a randomised comparison of immediate versus deferred ART initiation among HIV-positive persons with CD4(+) (cells/mm(3)) counts >500. Serum creatinine and urine dipstick protein were measured at Months 0, 1, 4, 8 and 12, and annually thereafter. The two arms were compared for changes in eGFR (mL/min/1.73 m(2), calculated by CKD-EPI equation), over time using longitudinal mixed models. Of 4685 START participants, 4629 (2294 in immediate and 2335 deferred arm) were included. Median baseline CD4(+) and eGFR were 651 and 111.5, respectively. ART was initiated in 2271 participants (99.0%) in the immediate and 1127 (48.3%) in the deferred arm, accounting for >94% and >19% of follow-up time, respectively. Overall, 89% started ART using a tenofovir-based regimen. Over 2.1 years median follow-up, mean eGFR was 0.56 (95% CI 0.003-1.11) higher in the immediate versus deferred arm, which was more prominent after adjustment for current tenofovir or bPI use (1.85, 95% CI 1.21-2.50) and in Black participants (30.1% overall) (3.90, 95% CI 2.84-4.97) versus non-Blacks (1.05, 95% CI 0.33-1.77) (P < 0.001 for interaction). Relative risk for proteinuria in the immediate versus deferred arm was 0.74 (95% CI 0.55-1.00) (P = 0.049). In the short-term, immediate ART initiation was associated with a modestly higher eGFR and lower proteinuria risk versus deferring ART (more pronounced in Black participants). Whether this early benefit translates into a lower risk of CKD requires further follow-up.
DOI: 10.1016/j.ijantimicag.2017.04.021
PubMed: 28668686
Links to Exploration step
pubmed:28668686Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.</title>
<author><name sortKey="Achhra, Amit C" sort="Achhra, Amit C" uniqKey="Achhra A" first="Amit C" last="Achhra">Amit C. Achhra</name>
<affiliation><nlm:affiliation>Kirby Institute, University of New South Wales, Sydney, NSW, Australia; NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY, USA. Electronic address: aachhra@kirby.unsw.edu.au.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mocroft, Amanda" sort="Mocroft, Amanda" uniqKey="Mocroft A" first="Amanda" last="Mocroft">Amanda Mocroft</name>
<affiliation><nlm:affiliation>University College London, London, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ross, Michael" sort="Ross, Michael" uniqKey="Ross M" first="Michael" last="Ross">Michael Ross</name>
<affiliation><nlm:affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ryom Nielson, Lene" sort="Ryom Nielson, Lene" uniqKey="Ryom Nielson L" first="Lene" last="Ryom-Nielson">Lene Ryom-Nielson</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, CHIP, Section 8632 Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Avihingsanon, Anchalee" sort="Avihingsanon, Anchalee" uniqKey="Avihingsanon A" first="Anchalee" last="Avihingsanon">Anchalee Avihingsanon</name>
<affiliation><nlm:affiliation>HIV-NAT, Thai Red Cross AIDS Research Centre and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bakowska, Elzbieta" sort="Bakowska, Elzbieta" uniqKey="Bakowska E" first="Elzbieta" last="Bakowska">Elzbieta Bakowska</name>
<affiliation><nlm:affiliation>Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Belloso, Waldo" sort="Belloso, Waldo" uniqKey="Belloso W" first="Waldo" last="Belloso">Waldo Belloso</name>
<affiliation><nlm:affiliation>Coordinación de Investigación Clínica Académica en Latinoamérica (CICAL) and Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Clarke, Amanda" sort="Clarke, Amanda" uniqKey="Clarke A" first="Amanda" last="Clarke">Amanda Clarke</name>
<affiliation><nlm:affiliation>Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Furrer, Hansjakob" sort="Furrer, Hansjakob" uniqKey="Furrer H" first="Hansjakob" last="Furrer">Hansjakob Furrer</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lucas, Gregory M" sort="Lucas, Gregory M" uniqKey="Lucas G" first="Gregory M" last="Lucas">Gregory M. Lucas</name>
<affiliation><nlm:affiliation>School of Medicine, Johns Hopkins University, Baltimore, MD, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ristola, Matti" sort="Ristola, Matti" uniqKey="Ristola M" first="Matti" last="Ristola">Matti Ristola</name>
<affiliation><nlm:affiliation>Division of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rassool, Mohammed" sort="Rassool, Mohammed" uniqKey="Rassool M" first="Mohammed" last="Rassool">Mohammed Rassool</name>
<affiliation><nlm:affiliation>Cardiovascular Pathophysiology and Genomics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ross, Jonathan" sort="Ross, Jonathan" uniqKey="Ross J" first="Jonathan" last="Ross">Jonathan Ross</name>
<affiliation><nlm:affiliation>University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Somboonwit, Charurut" sort="Somboonwit, Charurut" uniqKey="Somboonwit C" first="Charurut" last="Somboonwit">Charurut Somboonwit</name>
<affiliation><nlm:affiliation>Moroni College of Medicine, University of South Florida, Tampa, FL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sharma, Shweta" sort="Sharma, Shweta" uniqKey="Sharma S" first="Shweta" last="Sharma">Shweta Sharma</name>
<affiliation><nlm:affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wyatt, Christina" sort="Wyatt, Christina" uniqKey="Wyatt C" first="Christina" last="Wyatt">Christina Wyatt</name>
<affiliation><nlm:affiliation>University College London, London, UK. Electronic address: christina.wyatt@mssm.edu.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28668686</idno>
<idno type="pmid">28668686</idno>
<idno type="doi">10.1016/j.ijantimicag.2017.04.021</idno>
<idno type="wicri:Area/PubMed/Corpus">000E40</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E40</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.</title>
<author><name sortKey="Achhra, Amit C" sort="Achhra, Amit C" uniqKey="Achhra A" first="Amit C" last="Achhra">Amit C. Achhra</name>
<affiliation><nlm:affiliation>Kirby Institute, University of New South Wales, Sydney, NSW, Australia; NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY, USA. Electronic address: aachhra@kirby.unsw.edu.au.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mocroft, Amanda" sort="Mocroft, Amanda" uniqKey="Mocroft A" first="Amanda" last="Mocroft">Amanda Mocroft</name>
<affiliation><nlm:affiliation>University College London, London, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ross, Michael" sort="Ross, Michael" uniqKey="Ross M" first="Michael" last="Ross">Michael Ross</name>
<affiliation><nlm:affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ryom Nielson, Lene" sort="Ryom Nielson, Lene" uniqKey="Ryom Nielson L" first="Lene" last="Ryom-Nielson">Lene Ryom-Nielson</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, CHIP, Section 8632 Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Avihingsanon, Anchalee" sort="Avihingsanon, Anchalee" uniqKey="Avihingsanon A" first="Anchalee" last="Avihingsanon">Anchalee Avihingsanon</name>
<affiliation><nlm:affiliation>HIV-NAT, Thai Red Cross AIDS Research Centre and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bakowska, Elzbieta" sort="Bakowska, Elzbieta" uniqKey="Bakowska E" first="Elzbieta" last="Bakowska">Elzbieta Bakowska</name>
<affiliation><nlm:affiliation>Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Belloso, Waldo" sort="Belloso, Waldo" uniqKey="Belloso W" first="Waldo" last="Belloso">Waldo Belloso</name>
<affiliation><nlm:affiliation>Coordinación de Investigación Clínica Académica en Latinoamérica (CICAL) and Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Clarke, Amanda" sort="Clarke, Amanda" uniqKey="Clarke A" first="Amanda" last="Clarke">Amanda Clarke</name>
<affiliation><nlm:affiliation>Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Furrer, Hansjakob" sort="Furrer, Hansjakob" uniqKey="Furrer H" first="Hansjakob" last="Furrer">Hansjakob Furrer</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lucas, Gregory M" sort="Lucas, Gregory M" uniqKey="Lucas G" first="Gregory M" last="Lucas">Gregory M. Lucas</name>
<affiliation><nlm:affiliation>School of Medicine, Johns Hopkins University, Baltimore, MD, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ristola, Matti" sort="Ristola, Matti" uniqKey="Ristola M" first="Matti" last="Ristola">Matti Ristola</name>
<affiliation><nlm:affiliation>Division of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rassool, Mohammed" sort="Rassool, Mohammed" uniqKey="Rassool M" first="Mohammed" last="Rassool">Mohammed Rassool</name>
<affiliation><nlm:affiliation>Cardiovascular Pathophysiology and Genomics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ross, Jonathan" sort="Ross, Jonathan" uniqKey="Ross J" first="Jonathan" last="Ross">Jonathan Ross</name>
<affiliation><nlm:affiliation>University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Somboonwit, Charurut" sort="Somboonwit, Charurut" uniqKey="Somboonwit C" first="Charurut" last="Somboonwit">Charurut Somboonwit</name>
<affiliation><nlm:affiliation>Moroni College of Medicine, University of South Florida, Tampa, FL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sharma, Shweta" sort="Sharma, Shweta" uniqKey="Sharma S" first="Shweta" last="Sharma">Shweta Sharma</name>
<affiliation><nlm:affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wyatt, Christina" sort="Wyatt, Christina" uniqKey="Wyatt C" first="Christina" last="Wyatt">Christina Wyatt</name>
<affiliation><nlm:affiliation>University College London, London, UK. Electronic address: christina.wyatt@mssm.edu.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of antimicrobial agents</title>
<idno type="eISSN">1872-7913</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The impact of early ART initiation (versus deferring) on kidney function has not been studied. START was a randomised comparison of immediate versus deferred ART initiation among HIV-positive persons with CD4(+) (cells/mm(3)) counts >500. Serum creatinine and urine dipstick protein were measured at Months 0, 1, 4, 8 and 12, and annually thereafter. The two arms were compared for changes in eGFR (mL/min/1.73 m(2), calculated by CKD-EPI equation), over time using longitudinal mixed models. Of 4685 START participants, 4629 (2294 in immediate and 2335 deferred arm) were included. Median baseline CD4(+) and eGFR were 651 and 111.5, respectively. ART was initiated in 2271 participants (99.0%) in the immediate and 1127 (48.3%) in the deferred arm, accounting for >94% and >19% of follow-up time, respectively. Overall, 89% started ART using a tenofovir-based regimen. Over 2.1 years median follow-up, mean eGFR was 0.56 (95% CI 0.003-1.11) higher in the immediate versus deferred arm, which was more prominent after adjustment for current tenofovir or bPI use (1.85, 95% CI 1.21-2.50) and in Black participants (30.1% overall) (3.90, 95% CI 2.84-4.97) versus non-Blacks (1.05, 95% CI 0.33-1.77) (P < 0.001 for interaction). Relative risk for proteinuria in the immediate versus deferred arm was 0.74 (95% CI 0.55-1.00) (P = 0.049). In the short-term, immediate ART initiation was associated with a modestly higher eGFR and lower proteinuria risk versus deferring ART (more pronounced in Black participants). Whether this early benefit translates into a lower risk of CKD requires further follow-up.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28668686</PMID>
<DateCreated><Year>2017</Year>
<Month>07</Month>
<Day>02</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>05</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>50</Volume>
<Issue>3</Issue>
<PubDate><Year>2017</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>International journal of antimicrobial agents</Title>
<ISOAbbreviation>Int. J. Antimicrob. Agents</ISOAbbreviation>
</Journal>
<ArticleTitle>Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.</ArticleTitle>
<Pagination><MedlinePgn>453-460</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0924-8579(17)30230-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2017.04.021</ELocationID>
<Abstract><AbstractText>The impact of early ART initiation (versus deferring) on kidney function has not been studied. START was a randomised comparison of immediate versus deferred ART initiation among HIV-positive persons with CD4(+) (cells/mm(3)) counts >500. Serum creatinine and urine dipstick protein were measured at Months 0, 1, 4, 8 and 12, and annually thereafter. The two arms were compared for changes in eGFR (mL/min/1.73 m(2), calculated by CKD-EPI equation), over time using longitudinal mixed models. Of 4685 START participants, 4629 (2294 in immediate and 2335 deferred arm) were included. Median baseline CD4(+) and eGFR were 651 and 111.5, respectively. ART was initiated in 2271 participants (99.0%) in the immediate and 1127 (48.3%) in the deferred arm, accounting for >94% and >19% of follow-up time, respectively. Overall, 89% started ART using a tenofovir-based regimen. Over 2.1 years median follow-up, mean eGFR was 0.56 (95% CI 0.003-1.11) higher in the immediate versus deferred arm, which was more prominent after adjustment for current tenofovir or bPI use (1.85, 95% CI 1.21-2.50) and in Black participants (30.1% overall) (3.90, 95% CI 2.84-4.97) versus non-Blacks (1.05, 95% CI 0.33-1.77) (P < 0.001 for interaction). Relative risk for proteinuria in the immediate versus deferred arm was 0.74 (95% CI 0.55-1.00) (P = 0.049). In the short-term, immediate ART initiation was associated with a modestly higher eGFR and lower proteinuria risk versus deferring ART (more pronounced in Black participants). Whether this early benefit translates into a lower risk of CKD requires further follow-up.</AbstractText>
<CopyrightInformation>Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Achhra</LastName>
<ForeName>Amit C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo><Affiliation>Kirby Institute, University of New South Wales, Sydney, NSW, Australia; NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY, USA. Electronic address: aachhra@kirby.unsw.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mocroft</LastName>
<ForeName>Amanda</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>University College London, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ross</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ryom-Nielson</LastName>
<ForeName>Lene</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, CHIP, Section 8632 Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Avihingsanon</LastName>
<ForeName>Anchalee</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>HIV-NAT, Thai Red Cross AIDS Research Centre and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bakowska</LastName>
<ForeName>Elzbieta</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Belloso</LastName>
<ForeName>Waldo</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Coordinación de Investigación Clínica Académica en Latinoamérica (CICAL) and Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Clarke</LastName>
<ForeName>Amanda</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Furrer</LastName>
<ForeName>Hansjakob</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lucas</LastName>
<ForeName>Gregory M</ForeName>
<Initials>GM</Initials>
<AffiliationInfo><Affiliation>School of Medicine, Johns Hopkins University, Baltimore, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ristola</LastName>
<ForeName>Matti</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rassool</LastName>
<ForeName>Mohammed</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Cardiovascular Pathophysiology and Genomics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ross</LastName>
<ForeName>Jonathan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Somboonwit</LastName>
<ForeName>Charurut</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Moroni College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sharma</LastName>
<ForeName>Shweta</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wyatt</LastName>
<ForeName>Christina</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>University College London, London, UK. Electronic address: christina.wyatt@mssm.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>K24 DA035684</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 DK100272</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>UM1 AI120197</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 DA026770</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>UM1 AI068641</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P01 DK056492</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 DK112258</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>06</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int J Antimicrob Agents</MedlineTA>
<NlmUniqueID>9111860</NlmUniqueID>
<ISSNLinking>0924-8579</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2015 Apr;16 Suppl 1:55-63</RefSource>
<PMID Version="1">25711324</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Mar 20;9(3):e92717</RefSource>
<PMID Version="1">24651857</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2011 Nov;22(11):2129-37</RefSource>
<PMID Version="1">21997394</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet HIV. 2015 Jul;2(7):e288-98</RefSource>
<PMID Version="1">26423253</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Oct 23;23(16):2143-9</RefSource>
<PMID Version="1">19684507</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Aug 27;373(9):795-807</RefSource>
<PMID Version="1">26192873</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2010 Mar 24;303(12):1180-7</RefSource>
<PMID Version="1">20332404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Nephrol. 2014;2014:381985</RefSource>
<PMID Version="1">24800076</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2014 Aug;86(2):350-7</RefSource>
<PMID Version="1">24646860</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2016 May 12;11(5):e0155100</RefSource>
<PMID Version="1">27171281</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 1999 Mar 16;130(6):461-70</RefSource>
<PMID Version="1">10075613</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2009 May 5;150(9):604-12</RefSource>
<PMID Version="1">19414839</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Jun 12;375(9731):2073-81</RefSource>
<PMID Version="1">20483451</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Mar 27;23(6):689-96</RefSource>
<PMID Version="1">19262355</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Jul 31;24(12):1877-86</RefSource>
<PMID Version="1">20588170</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2015 Jun 27;385(9987):2606-15</RefSource>
<PMID Version="1">25890673</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2003 Apr 15;36(8):1070-3</RefSource>
<PMID Version="1">12684922</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Opin HIV AIDS. 2014 Jan;9(1):41-7</RefSource>
<PMID Version="1">24225381</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2014 Nov 1;59(9):e96-138</RefSource>
<PMID Version="1">25234519</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2015 Mar 31;12(3):e1001809</RefSource>
<PMID Version="1">25826420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatr Nephrol. 2015 Feb;30(2):193-8</RefSource>
<PMID Version="1">25370779</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr HIV/AIDS Rep. 2016 Jun;13(3):149-57</RefSource>
<PMID Version="1">27130284</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet HIV. 2016 Jan;3(1):e23-32</RefSource>
<PMID Version="1">26762990</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2011 Nov;22(11):1991-6</RefSource>
<PMID Version="1">21997397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Apr 24;26(7):867-75</RefSource>
<PMID Version="1">22313955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Nov 13;25(17):2149-55</RefSource>
<PMID Version="1">21857491</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):36-44</RefSource>
<PMID Version="1">25117929</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CKD</Keyword>
<Keyword MajorTopicYN="N">HAART</Keyword>
<Keyword MajorTopicYN="N">HIV</Keyword>
<Keyword MajorTopicYN="N">Kidney</Keyword>
<Keyword MajorTopicYN="N">START</Keyword>
<Keyword MajorTopicYN="N">eGFR</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>12</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>04</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>04</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pmc-release"><Year>2018</Year>
<Month>09</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>7</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>7</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>7</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28668686</ArticleId>
<ArticleId IdType="pii">S0924-8579(17)30230-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.ijantimicag.2017.04.021</ArticleId>
<ArticleId IdType="pmc">PMC5581703</ArticleId>
<ArticleId IdType="mid">NIHMS888880</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000E40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaSubSaharaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:28668686 |texte= Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28668686" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SidaSubSaharaV1
![]() | This area was generated with Dilib version V0.6.32. | ![]() |